Becker's Healthcare November 20, 2024
Mackenzie Bean

The FDA granted accelerated approved to the first gene therapy directly administered into the brain on Nov. 14.

The therapy, Kebilidi, was approved to treat adults and children with aromatic L-amino acid decarboxylase deficiency, a rare genetic disorder that affects the body’s ability to produce neurotransmitters that support motor function.

Kebilidi is administered via four infusions into a part of the brain...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech, Provider
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic
State Licensing Spotlight - Prescription medical device manufacturers & distributors: Regulatory considerations applicable to medical devices versus drugs
2025 Drugs to Watch: Market Access, Innovation, and the Future of Reimbursement
AbbVie gets into obesity with $350M deal for once-weekly shot

Share This Article